Aura Biosciences Inc (AURA)

Dec 2, 2024, 4:31 AM EST - 2 months ago

Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen

Oct 21, 2024, 3:12 PM EDT - 4 months ago

Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value

Oct 18, 2024, 9:16 AM EDT - 4 months ago

Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease

Oct 17, 2024, 4:05 PM EDT - 4 months ago

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

Oct 15, 2024, 12:40 PM EDT - 4 months ago

3 Small-Cap Stocks Ready to Deliver Significant Growth

FBRT TZOO

Sep 20, 2024, 3:30 PM EDT - 5 months ago

Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream +

APA CURI

Sep 17, 2024, 12:31 PM EDT - 5 months ago

Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company

Sep 12, 2024, 11:40 AM EDT - 5 months ago

Aura Biosciences Touts Promising Data From Eye Cancer Candidate

Sep 12, 2024, 6:30 AM EDT - 5 months ago

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

Sep 3, 2024, 4:05 PM EDT - 6 months ago

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024

Aug 28, 2024, 4:05 PM EDT - 6 months ago

Aura Biosciences to Participate in Upcoming Investor Conferences

Aug 26, 2024, 4:05 PM EDT - 6 months ago

Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting

Aug 8, 2024, 7:00 AM EDT - 7 months ago

Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights

May 30, 2024, 4:05 PM EDT - 9 months ago

Aura Biosciences to Participate in the Jefferies Global Healthcare Conference

May 23, 2024, 8:00 AM EDT - 9 months ago

Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024

May 9, 2024, 7:00 AM EDT - 10 months ago

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

Mar 27, 2024, 7:00 AM EDT - 11 months ago

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Dec 7, 2023, 8:00 AM EST - 1 year ago

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

Nov 15, 2023, 8:23 AM EST - 1 year ago

Aura Biosciences: Mid-2024 Data Could Bring Expansion Opportunity

Nov 9, 2023, 4:05 PM EST - 1 year ago

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Nov 6, 2023, 10:02 PM EST - 1 year ago

Aura Biosciences Announces Pricing of Public Offering of Common Stock

Nov 6, 2023, 4:08 PM EST - 1 year ago

Aura Biosciences Announces Proposed Public Offering of Common Stock

Nov 6, 2023, 3:00 PM EST - 1 year ago

Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma

Oct 31, 2023, 4:05 PM EDT - 1 year ago

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

Oct 2, 2023, 4:05 PM EDT - 1 year ago

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

Aug 9, 2023, 7:00 AM EDT - 1 year ago

Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

May 27, 2023, 8:00 AM EDT - 1 year ago

Aura Biosciences: Excellent Execution In The Large Ocular Cancer Market

May 12, 2023, 7:00 AM EDT - 1 year ago

Aura Biosciences to Participate in the JMP Securities Life Sciences Conference

May 11, 2023, 4:10 PM EDT - 1 year ago

Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Mar 15, 2023, 4:10 PM EDT - 2 years ago

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

Feb 16, 2023, 7:00 AM EST - 2 years ago

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration

Nov 10, 2022, 7:00 AM EST - 2 years ago

Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Nov 10, 2022, 6:45 AM EST - 2 years ago

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

Oct 3, 2022, 7:00 AM EDT - 2 years ago

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022

Sep 28, 2022, 7:00 AM EDT - 2 years ago

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Sep 27, 2022, 7:00 AM EDT - 2 years ago

Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022

Sep 7, 2022, 7:00 AM EDT - 2 years ago

Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress

Sep 1, 2022, 7:00 AM EDT - 2 years ago

Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress

Aug 11, 2022, 4:15 PM EDT - 2 years ago

Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Aug 2, 2022, 7:00 AM EDT - 2 years ago

Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference

Jul 19, 2022, 3:06 PM EDT - 2 years ago

JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer"

Jun 30, 2022, 8:51 AM EDT - 2 years ago

Aura's stock jumps 11% after announcing Fast Track status for its bladder cancer treatment candidate

Jun 30, 2022, 7:00 AM EDT - 2 years ago

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Jun 23, 2022, 8:56 AM EDT - 2 years ago

Aura Biosciences' Belzupacap Sarotalocan At Par With Plaque Radiotherapy In Eye Cancer

Jun 22, 2022, 4:30 PM EDT - 2 years ago

Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma

Jun 17, 2022, 7:00 AM EDT - 2 years ago

Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting

May 26, 2022, 5:26 PM EDT - 2 years ago

Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting

May 12, 2022, 4:15 PM EDT - 3 years ago

Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

May 3, 2022, 4:05 PM EDT - 3 years ago

Aura Biosciences Presents Preclinical Data Highlighting AU-011's Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

May 3, 2022, 7:00 AM EDT - 3 years ago

Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference